Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion

Giovanna Ferrari-Amorotti1, Valentina Fragliasso, Roza Esteki

  • 1Department of Clinical and Diagnostic Medicine, University of Modena and R. Emilia, Modena, Italy.

Cancer Research
|October 12, 2012
PubMed

Insights

Blocking the Snail/Slug-LSD1 interaction with Parnate or TAT-SNAG inhibits cancer cell invasion and motility. This approach targets cancer cell invasiveness without affecting proliferation, offering potential for novel anti-cancer drugs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Epithelial-mesenchymal transition (EMT) drives cancer cell invasion.
  • Snail and Slug transcription factors regulate EMT via epigenetic mechanisms.
  • Lysine-specific demethylase 1 (LSD1/KDM1A) interacts with Snail/Slug's SNAG domain.

Purpose of the Study:

  • To investigate if blocking the Snail/Slug-LSD1 interaction inhibits cancer cell motility and invasiveness.
  • To evaluate the efficacy of LSD1 inhibitor Parnate and TAT-SNAG peptide in preclinical cancer models.

Main Methods:

  • Treatment of cancer cell lines with Parnate or TAT-SNAG.
  • Assessment of E-cadherin promoter activity, cell motility, and invasion.
  • Analysis of epithelial and mesenchymal markers.
  • Evaluation of bone marrow homing and engraftment of cancer cells.

Main Results:

  • Parnate and TAT-SNAG treatments inhibited Slug-dependent E-cadherin repression.
  • Both treatments suppressed cancer cell motility and invasion without affecting proliferation.
  • Effects were associated with epithelial marker induction and mesenchymal marker repression.
  • Parnate treatment reduced bone marrow homing/engraftment of Slug-expressing cells.

Conclusions:

  • Targeting Snail/Slug-LSD1 transcription repression complexes is a viable strategy.
  • This approach selectively inhibits the invasive potential of cancer cells.
  • Development of novel drugs targeting these complexes may offer new therapeutic avenues for cancer treatment.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...